Antifungal hypersensitivity reactions and cross-reactivity patterns.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
26
10
2021
medline:
15
12
2021
entrez:
25
10
2021
Statut:
ppublish
Résumé
The goal of this article is to provide an updated understanding and evidence-based approach where possible for antifungal hypersensitivity. This includes recognition of clinical phenotype, implications for cross-reactivity and diagnostic, and management strategy for immediate and delayed hypersensitivity reactions. Antifungal hypersensitivity reactions can be classified according to their latency (immediate or delayed) and clinical phenotype. The majority of the cases described in the literature are delayed T-cell mediated reactions of various severities but immediate reactions consistent with non-Immunoglobulin E (IgE)-mediated mast cell activation and IgE-mediated reactions have also been described. Ancillary information such as skin testing, drug challenge and ex vivo experimental approaches can aid causality assessments and inform antifungal class cross-reactivity, which help optimize antifungal prescribing and stewardship. This review will update the clinician on mechanisms of drug hypersensitivity as well as providing a structured approach to the recognition, diagnosis and management of antifungal hypersensitivity reaction.
Identifiants
pubmed: 34693920
doi: 10.1097/QCO.0000000000000786
pii: 00001432-202112000-00002
doi:
Substances chimiques
Antifungal Agents
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
559-572Subventions
Organisme : NIAID NIH HHS
ID : R21 AI139021
Pays : United States
Organisme : NIGMS NIH HHS
ID : P50 GM115305
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG010863
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152183
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI139021
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI154659
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Gross BN, Steib-Bauert M, Kern WV, et al. Hospital use of systemic antifungal drugs: a multicenter surveillance update from Germany. Infection 2015; 43:423–429.
Hamdy RF, Zaoutis TE, Seo SK. Antifungal stewardship considerations for adults and pediatrics. Virulence 2017; 8:658–672.
Lindsay J, Teh BW, Micklethwaite K, Slavin M. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis 2019; 32:538–545.
World Health Organization (WHO). Antimicrobial resistance: World Health Organization (WHO), 2020 [Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance .
Choi H, Kim JH, Seong H, et al. Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia from the health-care benefit expansion to include newer antifungal agents. Int J Infect Dis 2019; 83:49–55.
Munoz P, Bouza E, group Cs. The current treatment landscape: the need for antifungal stewardship programmes. J Antimicrob Chemother 2016; 71: (suppl 2): ii5–ii12.
Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin N Am 2016; 30:51–83.
Broyles AD, Banerji A, Castells M. Practical guidance for the evaluation and management of drug hypersensitivity: general concepts. J Allergy Clin Immunol Pract 2020; 8 (9S):S3–S15.
Gintjee TJ, Donnelley MA, Thompson GR 3rd. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi 2020; 6:28.
Eiden C, Peyriere H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007; 41:755–763.
Jean T, Kwong K. Successful desensitization of voriconazole in an immunosuppressed pediatric patient. J Allergy Clin Immunol Pract 2015; 3:637–638.
van Dijke CP, Veerman FR, Haverkamp HC. Anaphylactic reactions to ketoconazole. Br Med J (Clin Res Ed) 1983; 287:1673.
Ensina LF, Tanno LK, Motta AA, et al. Ketoconazole allergy. Clinics 2009; 64:373–374.
Neuhaus G, Pavic N, Pletscher M. Anaphylactic reaction after oral fluconazole. BMJ 1991; 302:1341.
Jariwala S, Vernon N, de Vos G. A novel method of desensitization for fluconazole hypersensitivity in a patient with AIDS. Ann Allergy Asthma Immunol 2011; 106:542–543.
Chen J, Song X, Yang P, Wang J. Appearance of anaphylactic shock after long-term intravenous itraconazole treatment. Ann Pharmacother 2009; 43:537–541.
Takahashi T, Hitani A, Yamada H, et al. Desenitization to fluconazole in an AIDS patient. Ann Pharmacother 2001; 35:642–643.
Bittleman DB, Stapleton J, Casale TB. Report of successful desensitization to itraconazole. J Allergy Clin Immunol 1994; 94 (2 Pt 1):270–271.
Craig TJ, Peralta F, Boggavarapu J. Desensitization for fluconazole hypersensitivity. J Allergy Clin Immunol 1996; 98:845–846.
Pinto A, Chan RC. Lack of allergic cross-reactivity between fluconazole and voriconazole. Antimicrob Agents Chemother 2009; 53:1715–1716.
Di Leo E, Nettis E, Priore MG, et al. Maculopapular rash due to fluconazole. Clin Exp Dermatol 2009; 34:404.
Bruni F, Di Altobrando A, Alessandrini A, et al. Delayed access and provision of dermatological care as a collateral damage of COVID-19-related fear: allergic contact dermatitis to fluconazole. Contact Dermatitis 2021; 84:354–356.
Romita P, Guarneri F, De Prezzo S, et al. Onychomadesis secondary to allergic contact dermatitis to tioconazole contained in a nail lacquer: description of three cases. Contact Dermatitis 2020; 82:242–243.
Perez-Mesonero R, Schneller-Pavelescu L, Ochando-Ibernon G, et al. Is tioconazole contact dermatitis still a concern? Bringing allergic contact dermatitis caused by topical tioconazole back into the spotlight. Contact Dermatitis 2019; 80:168–169.
Faria A, Goncalo S, Goncalo M, et al. Allergic contact dermatitis from tioconazole. Contact Dermatitis 1996; 35:250–252.
Heikkila H, Stubb S, Reitamo S. A study of 72 patients with contact allergy to tioconazole. Br J Dermatol 1996; 134:678–680.
Gibson G, Buckley A, Murphy GM. Allergic contact dermatitis from tioconazole without cross-sensitivity to other imidazoles. Contact Dermatitis 1994; 30:308.
Quirino AP, Barros MA. Contact dermatitis from tioconazole. Contact Dermatitis 1994; 30:240–241.
Piletta P, Pasche-Koo F, Saurat JH. Contact dermatitis from tioconazole mimicking ‘one hand two feet syndrome’. Contact Dermatitis 1993; 28:308.
Marren P, Powell S. Contact sensitivity to tioconazole and other imidazoles. Contact Dermatitis 1992; 27:129–130.
Brunelli D, Vincenzi C, Morelli R, Tosti A. Contact dermatitis from tioconazole. Contact Dermatitis 1992; 27:120.
Onayemi O, Aldridge RD, Shaw S. Allergic contact dermatitis from tioconazole. A report of 2 cases. Contact Dermatitis 1992; 26:193–194.
Izu R, Aguirre A, Gonzalez M, Diaz-Perez JL. Contact dermatitis from tioconazole with cross-sensitivity to other imidazoles. Contact Dermatitis 1992; 26:130–131.
Jones SK, Kennedy CT. Contact dermatitis from tioconazole. Contact Dermatitis 1990; 22:122–123.
Baes H. Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles. Contact Dermatitis 1991; 24:89–93.
Khan M, Paul N, Fernandez C, Wakelin S. Fluconazole-induced fixed drug eruption confirmed by extemporaneous patch testing. Contact Dermatitis 2020; 83:507–508.
Demir S, Cetin EA, Unal D, et al. Generalized fixed drug eruption induced by fluconazole without cross-reactivity to itraconazole: lymphocyte transformation test confirms the diagnosis. Drug Saf Case Rep 2018; 5:2.
Fabre B, Albes B, Belhadjali H, Bazex J. Acute generalized exanthematous pustulosis due to fluconazole. Ann Dermatol Venereol 2002; 129:294–297.
Alsadhan A, Taher M, Krol A. Acute generalized exanthematous pustulosis induced by oral fluconazole. J Cutan Med Surg 2002; 6:122–124.
Heymann WR, Manders SM. Itraconazole-induced acute generalized exanthemic pustulosis. J Am Acad Dermatol 1995; 33:130–131.
Park YM, Kim JW, Kim CW. Acute generalized exanthematous pustulosis induced by itraconazole. J Am Acad Dermatol 1997; 36 (5 Pt 1):794–796.
Cancado GG, Fujiwara RT, Freitas PA, et al. Acute generalized exanthematous pustulosis induced by itraconazole: an immunological approach. Clin Exp Dermatol 2009; 34:e709–e711.
Gussenhoven MJ, Haak A, Peereboom-Wynia JD, van ’t Wout JW. Stevens-Johnson syndrome after fluconazole. Lancet 1991; 338:120.
Monastirli A, Pasmatzi E, Vryzaki E, et al. Fluconazole-induced Stevens-Johnson syndrome in a HIV-negative patient. Acta Derm Venereol 2008; 88:521–522.
Antony R, Fernandez A, Lekshmi S, et al. Case report on Fluconazole Induced stevens - Johnson Syndrome. Research J Pharm and Tech 2019; 12:3735–3738.
Azon-Masoliver A, Vilaplana J. Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection. Dermatology 1993; 187:268–269.
Ofoma UR, Chapnick EK. Fluconazole induced toxic epidermal necrolysis: a case report. Cases J 2009; 2:9071.
Pasmatzi E, Monastirli A, Georgiou S, et al. Short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients. J Drugs Dermatol 2011; 10:1360.
Keshri UP, Kumar N, Kumar R, Gari M. Fluconazole-induced Stevens-Jonson syndrome. Int J Basis Clin Pharmacol 2014; 3:556–558.
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60–68.
Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35–44.
Lash B, Jolliff J, Munoz A, Heidari A. Cross-reactivity between voriconazole, fluconazole and itraconazole. J Clin Pharm Ther 2016; 41:566–567.
Dooms-Goossens A, Matura M, Drieghe J, Degreef H. Contact allergy to imidazoles used as antimycotic agents. Contact Dermatitis 1995; 33:73–77.
Stubb S, Heikkila H, Reitamo S, Forstrom L. Contact allergy to tioconazole. Contact Dermatitis 1992; 26:155–158.
Cavassin FB, Bau-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of Amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections. Infect Dis Ther 2021; 10:115–147.
Shadur B, Trahair TN, O’Brien T, et al. Desensitisation to liposomal amphotericin B. J Allergy Clin Immunol Pract 2017; 5:181–183.
Dhindsa-Castanedo L, Narra M. Desensitization to liposomal amphotericin b after anaphylactic reaction. J Allergy Clin Immunol 2012; 129:AB105.
Kemp SF, Lockey RF. Amphotericin B: emergency challenge in a neutropenic, asthmatic patient with fungal sepsis. J Allergy Clin Immunol 1995; 96:425–427.
Drewett GP, Copaescu A, DeLuca J, et al. Asystolic cardiac arrest following liposomal amphotericin B infusion: anaphylaxis or compliment activation-related pseudoallergy? Allergy Asthma Clin Immunol 2021; 17:80.
Szebeni J, Bedocs P, Rozsnyay Z, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 2012; 8:176–184.
Kuchler A, Hamm H, Weidenthaler-Barth B, et al. Acute generalized exanthematous pustulosis following oral nystatin therapy: a report of three cases. Br J Dermatol 1997; 137:808–811.
Poszepczynska-Guigne E, Viguier M, Assier H, et al. [Acute generalized exanthematous pustulosis induced by drugs with low-digestive absorption: acarbose and nystatin]. Ann Dermatol Venereol 2003; 130:439–442.
Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 2017; 45:737–779.
Patel S, Alangaden GJ, Lum LG, et al. Immediate cross-hypersensitivity between micafungin and caspofungin: a case report. J Oncol Pharm Pract 2009; 15:187–189.
Cleary JD, Schwartz M, Rogers PD, et al. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 2003; 23:966–973.
Lee MC, Ni YW, Wang CH, et al. Caspofungin-induced severe toxic epidermal necrolysis. Ann Pharmacother 2010; 44:1116–1118.
Duckworth L, Maheshwari MB, Thomson MA. A diagnostic challenge: acute generalized exanthematous pustulosis or pustular psoriasis due to terbinafine. Clin Exp Dermatol 2012; 37:24–27.
Hall AP, Tate B. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australas J Dermatol 2000; 41:42–45.
Kempinaire A, De Raeve L, Merckx M, et al. Terbinafine-induced acute generalized exanthematous pustulosis confirmed by a positive patch-test result. J Am Acad Dermatol 1997; 37:653–655.
Beltraminelli HS, Lerch M, Arnold A, et al. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol 2005; 152:780–783.
Eyler JT, Squires S, Fraga GR, et al. Two cases of acute generalized exanthematous pustulosis related to oral terbinafine and an analysis of the clinical reaction pattern. Dermatol Online J 2012; 18:5.
Lombardo M, Cerati M, Pazzaglia A. Acute generalized exanthematous pustulosis induced by terbinafine. J Am Acad Dermatol 2003; 49:158–159.
Fontana RJ, Cirulli ET, Gu J, et al. The role of HLA-A∗33:01 in patients with cholestatic hepatitis attributed to terbinafine. J Hepatol 2018; 69:1317–1325.
Lazarov A, Livni E, Halevy S. Generalized pustular drug eruptions: confirmation by in vitro tests. J Eur Acad Dermatol Venereol 1998; 10:36–41.
Smith RJ, Boos MD, McMahon P. Probable griseofulvin-induced drug reaction with eosinophilia and systemic symptoms in a child. Pediatr Dermatol 2016; 33:e290–e291.
Maiolo C, Ross C, Ibbetson J, Kearney D. Griseofulvin associated with drug reaction with eosinophilia and systemic symptoms (DRESS). JAAD Case Rep 2016; 2:315–316.
Correia O, Delgado L, Resende C. [Lyell's syndrome and griseofulvin]. Ann Fr Anesth Reanim 1991; 10:493.
Taylor B, Duffill M. Toxic epidermal necrolysis from griseofulvin. J Am Acad Dermatol 1988; 19:565–567.
Kotani S, Hirose S, Niiya K, et al. Anaphylaxis to flucytosine in a patient with AIDS. JAMA 1988; 260:3275–3276.
Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68:702–712.
Joint Task Force on Practice Parameters, American Academy of Allergy Asthma Immunology, American College of Allergy Asthma Immunology, Joint Council of Allergy Asthma Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259–273.
Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003; 112:629–630.
Heinzerling L, Mari A, Bergmann KC, et al. The skin prick test - European standards. Clin Transl Allergy 2013; 3:3.
Empedrad R. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003; 112:629–630.
Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol 2019; 143:66–73.
Randolph C, Kaplan C, Fraser B. Rapid desensitization to fluconazole (Diflucan). Ann Allergy Asthma Immunol 2008; 100:616–617.
Quero R. Allergic reaction to griseofulvin. J Invest Dermatol 1960; 34:283–284.
Lehloenya RJ, Peter JG, Copascu A, et al. Delabeling delayed drug hypersensitivity: how far can you safely go? J Allergy Clin Immunol Pract 2020; 8:2878–2895. e6.
Copaescu A, Gibson A, Li Y, et al. An updated review of the diagnostic methods in delayed drug hypersensitivity. Front Pharmacol 2020; 11:573573.
Tavallaee M, Rad MM. Fixed drug eruption resulting from fluconazole use: a case report. J Med Case Rep 2009; 3:7368.
Goel A, Jain C. Fluconazole induced fixed drug eruption: a rare offender. J Dermatol 2004; 31:345–346.
Heikkila H, Timonen K, Stubb S. Fixed drug eruption due to fluconazole. J Am Acad Dermatol 2000; 42 (5 Pt 2):883–884.
Ochando-Ibernon G, Schneller-Pavelescu L, Vergara de Caso EF, Silvestre-Salvador JF. Allergic contact dermatitis caused by undecylenic acid in an antifungal nail solution. Contact Dermatitis 2019; 80:313–314.
Sanchez-Borges M, Gonzalez-Aveledo LA. Fixed drug eruptions induced by cross-reactive imidazoles. Allergol Immunopathol 2011; 39:246–247.
Zwiener R, Marino G, Danna M, et al. Successful desensitization to voriconazole. J Allergy Clin Immunol 2013; 131:AB166.
Ward S, Maciag MC, Jones S, et al. Successful rapid desensitization to micafungin in a pediatric patient. Pediatr Allergy Immunol Pulmonol 2020; 34:106–108.
Abbott M, Hughes DL, Patel R, Kinghorn GR. Angio-oedema after fluconazole. Lancet 1991; 338:633.
Morales MK, Harris C, Shoham S. Graded isavuconazole introduction in a patient with voriconazole allergy. Transpl Infect Dis 2017; 19:1–6.
George J, Sharma A, Dixit R, et al. Toxic epidermal necrolysis caused by fluconazole in a patient with human immunodeficiency virus infection. J Pharmacol Pharmacother 2012; 3:276–278.